We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Danaher Purchases Life Science Businesses for US $1.1 Billion

By LabMedica International staff writers
Posted on 07 Sep 2009
Danaher Corp. More...
(DHR; Washington, DC, USA) will acquire life science instrumentation businesses from MDS Inc. (Mississauga, ON, Canada) and Life Technologies (Carlsbad, CA, USA). The company has signed a definitive agreement with MDS Inc. to acquire its analytical technologies division, which includes a 50% ownership position in Applied Biosystems (Foster City, CA, USA)/MDS Sciex joint venture (AB Sciex), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation (Sunnyvale, CA, USA), a bioresearch and analytical instrumentation company.

In a separate but related transaction, Danaher signed a definitive agreement with Life Technologies Corp. to acquire the remaining 50% ownership position in AB Sciex. After completion of both transactions, Danaher will own outright AB Sciex and MDS. The aggregate purchase price for the combined transactions is $1.1 billion, including debt assumed and net of cash acquired.

The transaction with MDS Inc. is subject to approval of the MDS shareholders. Both transactions are subject to regulatory approval and customary closing conditions, including the absence of material adverse change with respect to the acquired businesses. Danaher expects the transactions to close in the fourth quarter of 2009.

The acquired businesses will operate within Danaher's medical technologies segment and will expand the segment's annual revenues by more than $650 million. Danaher's life sciences and diagnostics annual revenues will increase to more than $2 billion.

AB Sciex designs and manufactures mass spectrometers, and instruments used by clinicians and researchers to identify and quantify specific molecules in complex samples. Typical applications include diagnostics testing, drug development, food and environmental safety testing, and proteomics research. MDS supplies bioanalytical instrumentation.

Danaher designs, manufactures, and markets products and services to professional, medical, industrial, and commercial customers. Its portfolio of brands is well recognized in each of its markets.

Related Links:
Danaher Corp.
MDS Inc.
AB Sciex
Life Technologies Corp.
Molecular Devices Corporation



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.